FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients

Ayman Soubra, Mehmet Gencturk, Jerry W Froelich, Priya Balaji, Shilpa Gupta, Gautam Jha, Badrinath R Konety

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The purpose of this study was to assess the accuracy of 18F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) scans in measuring the response to neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer. FDG-PET/CT had 78.5% sensitivity (95.6% specificity) in identifying complete pathologic response and 83% sensitivity (94% specificity) for the detection of chemosensitive tumors. FDG-PET/CT can help determine the response of primary tumor to NAC in patients with muscle-invasive bladder cancer and thus can more accurately predict prognosis. Purpose: To determine the accuracy of 18F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) scans in assessing the response to neoadjuvant chemotherapy (NAC) in patients with bladder cancer scheduled to undergo radical cystectomy (RC). Patients and Methods: All patients treated at our center for muscle-invasive bladder cancer (MIBC) were counseled and offered NAC before RC. FDG-PET/CT scans were performed before the initiation of chemotherapy and after completion of the regimen. Patients with disease with complete response to NAC were those who had (pT0) or residual carcinoma-in-situ (pTis) on final pathology. Those who were downstaged from MIBC to non-MIBC were considered to have a chemosensitive tumor. We used percentage reduction in standardized maximum uptake value (SUVmax) from PET/CT scans as our measure to correlate with the final pathology after cystectomy. Results: Thirty-seven patients with MIBC who underwent NAC followed by RC were included in the final analysis. FDG-PET/CT had 75% sensitivity (89.66% specificity) in identifying those with complete pathologic response with a 100% change in SUVmax, and 83% sensitivity (94% specificity) for the detection of chemosensitive tumors. Conclusion: FDG-PET/CT can help determine the response of primary tumor to NAC in patients with MIBC and thus can more accurately predict the prognosis of the patients, or potentially the appropriate time for cystectomy.

Original languageEnglish (US)
Pages (from-to)360-364
Number of pages5
JournalClinical Genitourinary Cancer
Volume16
Issue number5
DOIs
StatePublished - Oct 2018

Keywords

  • Clinical response
  • Pathologic stage
  • Urinary bladder neoplasms
  • Urothelial carcinoma

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients'. Together they form a unique fingerprint.

Cite this